Isotretinoin Associated Rhabdomyolysis: Monitoring Creatine Kinase and Educating Patients.

Autor:	Fayiga FF; Children's Skin Center, Nicklaus Children's Hospital, Miami, Florida, USA.; Division of Dermatology, Department of Pediatrics, Nicklaus Children's Hospital, Miami, Florida, USA.; The Philip Frost Department of Dermatology and Cutaneous Surgery at The University of Miami Miller School of Medicine, Miami, Florida, USA., Reyes-Hadsall SC; University of Miami Miller School of Medicine, Miami, Florida, USA., Sebastiany LC; Community Health of South Florida Inc., Miami, Florida, USA., Arutyunyan S; Larkin Community Hospital, Miami, Florida, USA., Wong A; Lake Erie College of Osteopathic Medicine, Bradenton, Florida, USA., Duarte AM; Children's Skin Center, Nicklaus Children's Hospital, Miami, Florida, USA.; Division of Dermatology, Department of Pediatrics, Nicklaus Children's Hospital, Miami, Florida, USA.; The Philip Frost Department of Dermatology and Cutaneous Surgery at The University of Miami Miller School of Medicine, Miami, Florida, USA.; Department of Dermatology, Florida International University Herbert Wertheim College of Medicine, Miami, Florida, USA.; Department of Internal Medicine and Division of Dermatology, Nova Southeastern University, Miami, Florida, USA.
Jazyk:	angličtina
Zdroj:	Skin appendage disorders [Skin Appendage Disord] 2021 Nov; Vol. 7 (6), pp. 493-498. Date of Electronic Publication: 2021 Jul 28.
DOI:	10.1159/000517831
Abstrakt:	Monitoring specific values at baseline and throughout treatment is standard of care for isotretinoin therapy; however, creatine kinase (CK) blood monitoring is often excluded. Herein, we describe the importance of CK monitoring during isotretinoin therapy to assess the risk of rhabdomyolysis and potential renal damage, regardless of muscle-related symptom presentation. We present 2 patients with hyperCKemia: a 16-year-old male on isotretinoin whose CK levels were elevated (7,325 U/L) when rhabdomyolysis symptoms were present, and an asymptomatic 18-year-old male with elevated CK levels (35,000 U/L) before starting isotretinoin. Based on our experience, we strongly recommend obtaining CK levels to monitor for and potentially prevent rhabdomyolysis and its associated complications. Competing Interests: Ana M. Duarte, MD is an investigator for Pfizer, Novartis, UCB Biopharma. She is also a speaker for Sanofi Regeneron, Pfizer, and Pierre Fabre. The other authors have no conflicts of interest relevant to this article to disclose. (Copyright © 2021 by S. Karger AG, Basel.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu